<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Flow Medical Dashboard</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.9.1/chart.min.js"></script>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chartjs-plugin-annotation@3.0.1/dist/chartjs-plugin-annotation.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
   
    <!-- <script src="https://cdn.jsdelivr.net/npm/chart.js@4.4.0/dist/chart.min.js"></script> -->
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap');
        body {
            font-family: 'Inter', sans-serif;
        }
        .fade-in {
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            0% { opacity: 0; transform: translateY(10px); }
            100% { opacity: 1; transform: translateY(0); }
        }
        .card-hover:hover {
            transform: translateY(-2px);
            box-shadow: 0 10px 20px rgba(0, 0, 0, 0.1);
        }
        .collapsible-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.3s ease-out;
        }
        .collapsible-content.active {
            max-height: 1000px;
        }
        canvas {
            max-height: 400px;
        }
    </style>
</head>
<body class="bg-gray-100 dark:bg-gray-900 text-gray-900 dark:text-gray-100 transition-colors duration-300">
    <div class="container mx-auto px-4 sm:px-6 lg:px-8 py-12 min-h-screen">
        <!-- Header -->
        <header class="bg-white dark:bg-gray-800 rounded-2xl shadow-lg p-8 mb-8 flex flex-col md:flex-row justify-between items-start fade-in">
            <div>
                <h1 class="text-4xl font-bold mb-2">Flow Medical Dashboard</h1>
                <p class="text-lg text-gray-600 dark:text-gray-300">tDCS: Depression & Potential Epilepsy Crossover</p>
            </div>
            <div class="text-right mt-4 md:mt-0">
                <p class="text-sm text-gray-500 dark:text-gray-400">Last Updated: April 25, 2025</p>
                <p class="text-sm text-gray-500 dark:text-gray-400">Data as of March 31, 2025</p>
            </div>
        </header>

        <!-- AI Summary -->
        <section class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 mb-8 fade-in">
            <h2 class="text-2xl font-semibold mb-4">AI-Generated Summary</h2>
            <p class="text-gray-600 dark:text-gray-300">
                Flow Neuroscience’s tDCS headset, with over 14,000 users in 2024, is a proven depression treatment, backed by NHS trials and CE-marking 
                <a href="https://www.flowneuroscience.com/results/" class="text-blue-500 hover:underline" target="_blank">[Flow Neuroscience]</a>. 
                Its potential epilepsy market entry is constrained by no epilepsy-specific trials as of April 2025, despite a $551.1M epilepsy device market growing at 5.7% CAGR 
                <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">[Credence Research]</a>. 
                The 33% depression comorbidity in epilepsy (16.5M patients) offers a crossover opportunity, but regulatory hurdles and competition from VNS/DBS pose risks 
 Itália            <a href="https://www.epilepsy.com/complications-risks/moods-behavior/depression" class="text-blue-500 hover:underline" target="_blank">[Epilepsy Foundation]</a>. 
                Flow’s $10.5M funding supports depression-focused R&D, but epilepsy expansion requires clinical investment 
                <a href="https://www.siliconrepublic.com/start-ups/flow-neuroscience-series-a-funding" class="text-blue-500 hover:underline" target="_blank">[Silicon Republic]</a>. 
                Strategic partnerships or trials targeting comorbid patients could unlock growth by 2030, potentially capturing 5–10% of the epilepsy market.
            </p>
            <p class="text-xs text-gray-500 dark:text-gray-400 mt-3">
                Generated by Grok 3, xAI, April 25, 2025
            </p>
        </section>

        <!-- Key Metrics -->
        <section class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 card-hover transition-all fade-in">
                <h3 class="text-sm font-semibold text-gray-500 dark:text-gray-400">Epilepsy Market Size (2024)</h3>
                <p class="mt-2 text-2xl font-bold">$551.1M</p>
                <p class="text-sm text-gray-600 dark:text-gray-300">Epilepsy Monitoring Devices</p>
                <p class="text-xs text-blue-500 mt-2">
                    <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="hover:underline" target="_blank">Source: Credence Research</a>
                </p>
            </div>
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 card-hover transition-all fade-in">
                <h3 class="text-sm font-semibold text-gray-500 dark:text-gray-400">tDCS Market Size (2024)</h3>
                <p class="mt-2 text-2xl font-bold">$1.471B</p>
                <p class="text-sm text-gray-600 dark:text-gray-300">Transcranial Direct Current Stimulation Market</p>
                <p class="text-xs text-blue-500 mt-2">
                    <a href="https://www.openpr.com/news/3635127/transcranial-direct-current-stimulation-market-to-reach-usd" class="hover:underline" target="_blank">Source: openPR</a>
                </p>
            </div>
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 card-hover transition-all fade-in">
                <h3 class="text-sm font-semibold text-gray-500 dark:text-gray-400">Funding Raised</h3>
                <p class="mt-2 text-2xl font-bold">$9M</p>
                <p class="text-sm text-gray-600 dark:text-gray-300">August 2021 (Series A)</p>
                <p class="text-xs text-blue-500 mt-2">
                    <a href="https://www.siliconrepublic.com/start-ups/flow-neuroscience-series-a-funding" class="hover:underline" target="_blank">Source: Silicon Republic</a>
                </p>
            </div>
        </section>

        <!-- Charts -->
        <section class="grid grid-cols-1 lg:grid-cols-2 gap-6 mb-8">
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md overflow-hidden fade-in">
                <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                    <h2 class="text-xl font-semibold">Market Growth Trends</h2>
                    <p class="text-xs text-gray-500 dark:text-gray-400 mt-1">
                        Sources: 
                        <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">Credence Research (Epilepsy)</a>, 
                        <a href="https://www.openpr.com/news/3635127/transcranial-direct-current-stimulation-market-to-reach-usd" class="text-blue-500 hover:underline" target="_blank">openPR (tDCS)</a>
                    </p>
                </div>
                <div class="p-6">
                    <canvas id="flowmedical-market-growth"></canvas>
                </div>
            </div>
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md overflow-hidden fade-in">
                <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                    <h2 class="text-xl font-semibold">Comorbidity Reach</h2>
                    <p class="text-xs text-gray-500 dark:text-gray-400 mt-1">
                        Source: <a href="https://www.epilepsy.com/complications-risks/moods-behavior/depression" class="text-blue-500 hover:underline" target="_blank">Epilepsy Foundation</a>
                    </p>
                </div>
                <div class="p-6">
                    <canvas id="flowmedical-comorbidity-reach"></canvas>
                </div>
            </div>
        </section>

        <!-- Additional Charts -->
        <section class="grid grid-cols-1 lg:grid-cols-2 gap-6 mb-8">
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md overflow-hidden fade-in">
                <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                    <h2 class="text-xl font-semibold">tDCS Technology Adoption</h2>
                    <p class="text-xs text-gray-500 dark:text-gray-400 mt-1">
                        Source: <a href="https://www.flowneuroscience.com/results/" class="text-blue-500 hover:underline" target="_blank">Flow Neuroscience (2024, estimated)</a>
                    </p>
                </div>
                <div class="p-6">
                    <canvas id="flowmedical-tech-adoption"></canvas>
                </div>
            </div>
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md overflow-hidden fade-in">
                <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                    <h2 class="text-xl font-semibold">Funding Timeline</h2>
                    <p class="text-xs text-gray-500 dark:text-gray-400 mt-1">
                        Sources: 
                        <a href="https://www.selectscience.net/article/medical-device-company-flow-neuroscience-raises-usd1-5m-to-transform-treatment-of-depression" class="text-blue-500 hover:underline" target="_blank">SelectScience (Seed)</a>, 
                        <a href="https://www.siliconrepublic.com/start-ups/flow-neuroscience-series-a-funding" class="text-blue-500 hover:underline" target="_blank">Silicon Republic (Series A)</a>
                    </p>
                </div>
                <div class="p-6">
                    <canvas id="flowmedical-funding"></canvas>
                </div>
            </div>
        </section>

        <!-- Insights -->
        <section class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-8">
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 fade-in">
                <h2 class="text-xl font-semibold mb-4">Epilepsy Market Potential</h2>
                <p class="text-gray-600 dark:text-gray-300">
                    Flow Neuroscience’s tDCS headset, CE-marked for depression since 2019, serves over 400 NHS patients and is expanding to 15 UK trusts as of October 2024 
                    <a href="https://www.theguardian.com/society/2025/jan/11/is-a-brain-stimulation-headset-the-answer-to-depression" class="text-blue-500 hover:underline" target="_blank">[Guardian]</a>. 
                    No epilepsy-specific trials exist as of April 2025, limiting direct market entry into the $551.1M epilepsy device market 
                    <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">[Credence Research]</a>. 
                    The 33% comorbidity rate (16.5M patients) offers a crossover opportunity, but competition from VNS/DBS and regulatory barriers pose challenges 
                    <a href="https://www.epilepsy.com/complications-risks/moods-behavior/depression" class="text-blue-500 hover:underline" target="_blank">[Epilepsy Foundation]</a>. 
                    Flow could capture 5–10% of the market by 2030 with $20–$30M in epilepsy trial funding.
                </p>
                <p class="mt-2 text-gray-600 dark:text-gray-300">
                    <span class="font-semibold">SWOT Analysis:</span><br>
                    <strong>Strengths:</strong> Low-cost, home-use tDCS; NHS adoption; FDA review underway 
                    <a href="https://www.medscape.com/viewarticle/diy-brain-stim-growing-popularity-safe-effective-2024a1000ij5" class="text-blue-500 hover:underline" target="_blank">[Medscape]</a>.<br>
                    <strong>Weaknesses:</strong> No epilepsy trials; limited neurology expertise.<br>
                    <strong>Opportunities:</strong> Comorbid patient market; epilepsy market growth to $858.67M by 2032.<br>
                    <strong>Threats:</strong> Competitors (Medtronic, NeuroPace); stringent regulations.
                </p>
                <p class="text-xs text-gray-500 dark:text-gray-400 mt-3">
                    Sources: 
                    <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">Credence Research</a>, 
                    <a href="https://www.fortunebusinessinsights.com/epilepsy-drugs-market-106908" class="text-blue-500 hover:underline" target="_blank">Fortune Business Insights</a>
                </p>
            </div>
            <div class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 fade-in">
                <h2 class="text-xl font-semibold mb-4">Technology Details</h2>
                <p class="text-gray-600 dark:text-gray-300">
                    Flow’s tDCS headset delivers low-intensity currents to the dorsolateral prefrontal cortex, approved for home use in UK/EU 
                    <a href="https://www.flowneuroscience.com/" class="text-blue-500 hover:underline" target="_blank">[Flow Neuroscience]</a>. 
                    It’s under FDA review for depression, with trials showing efficacy over antidepressants 
                    <a href="https://www.medscape.com/viewarticle/diy-brain-stim-growing-popularity-safe-effective-2024a1000ij5" class="text-blue-500 hover:underline" target="_blank">[Medscape]</a>.
                </p>
                <p class="text-sm mt-3 text-gray-500 dark:text-gray-400">Key Features:</p>
                <ul class="mt-1 text-sm text-gray-600 dark:text-gray-300 space-y-1">
                    <li>• Non-invasive tDCS, 400x weaker than ECT</li>
                    <li>• Bluetooth app with telemedicine support</li>
                    <li>• 30-minute sessions, 5–6 weeks</li>
                    <li>• Over 14,000 depression users (2024, estimated)</li>
                </ul>
                <p class="text-xs text-gray-500 dark:text-gray-400 mt-3">
                    Sources: 
                    <a href="https://www.flowneuroscience.com/results/" class="text-blue-500 hover:underline" target="_blank">Flow Neuroscience</a>, 
                    <a href="https://www.leicspart.nhs.uk/about/news/lpt-pilots-new-innovative-headsets-help-to-treat-patients-with-severe-depression/" class="text-blue-500 hover:underline" target="_blank">NHS Leicestershire</a>
                </p>
            </div>
        </section>

        <!-- Calculations -->
        <section class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 mb-8 fade-in">
            <h2 class="text-xl font-semibold mb-4">Calculations & Methodology</h2>
            <div>
                <button class="text-blue-500 font-semibold mb-2 hover:underline" onclick="toggleCollapsible('epilepsy-calc')">Epilepsy Market Growth</button>
                <div id="epilepsy-calc" class="collapsible-content">
                    <p class="text-gray-600 dark:text-gray-300">
                        <strong>Raw Data:</strong> $551.1M (2024), $858.67M (2032) 
                        <a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">[Credence Research]</a>.<br>
                        <strong>Formula:</strong> CAGR = ((End Value / Start Value)^(1/Number of Years)) - 1<br>
                        <strong>Steps:</strong><br>
                        1. End Value = $858.67M, Start Value = $551.1M, Years = 8 (2024–2032).<br>
                        2. CAGR = ((858.67 / 551.1)^(1/8)) - 1 = 0.057 or 5.7%.<br>
                        3. Annual Values: Value_n = 551.1 * (1 + 0.057)^n, where n = years from 2024.<br>
                        <strong>Results:</strong> [551.1, 582.5, 615.7, 650.8, 687.9, 727.1, 768.5, 812.3, 858.67] ($M).
                    </p>
                </div>
            </div>
            <div>
                <button class="text-blue-500 font-semibold mb-2 hover:underline" onclick="toggleCollapsible('tdcs-calc')">tDCS Market Growth</button>
                <div id="tdcs-calc" class="collapsible-content">
                    <p class="text-gray-600 dark:text-gray-300">
                        <strong>Raw Data:</strong> $1.346B (2023), $2.742B (2031) 
                        <a href="https://www.openpr.com/news/3635127/transcranial-direct-current-stimulation-market-to-reach-usd" class="text-blue-500 hover:underline" target="_blank">[openPR]</a>.<br>
                        <strong>Formula:</strong> CAGR = ((End Value / Start Value)^(1/Number of Years)) - 1<br>
                        <strong>Steps:</strong><br>
                        1. End Value = $2.742B, Start Value = $1.346B, Years = 8 (2023–2031).<br>
                        2. CAGR = ((2.742 / 1.346)^(1/8)) - 1 = 0.0929 or 9.29%.<br>
                        3. Annual Values: Value_n = 1.346 * (1 + 0.0929)^n, where n = years from 2023.<br>
                        <strong>Results:</strong> [1.346, 1.471, 1.608, 1.757, 1.920, 2.099, 2.294, 2.507, 2.742] ($B).
                    </p>
                </div>
            </div>
            <div>
                <button class="text-blue-500 font-semibold mb-2 hover:underline" onclick="toggleCollapsible('comorbidity-calc')">Comorbidity Reach</button>
                <div id="comorbidity-calc" class="collapsible-content">
                    <p class="text-gray-600 dark:text-gray-300">
                        <strong>Raw Data:</strong> 50M epilepsy patients, 33% with depression 
                        <a href="https://www.epilepsy.com/complications-risks/moods-behavior/depression" class="text-blue-500 hover:underline" target="_blank">[Epilepsy Foundation]</a>.<br>
                        <strong>Formula:</strong> Comorbid Patients = Total Patients * Comorbidity Rate<br>
                        <strong>Steps:</strong><br>
                        1. Total Patients = 50M, Comorbidity Rate = 0.33.<br>
                        2. Comorbid Patients = 50M * 0.33 = 16.5M.<br>
                        3. Non-Comorbid Patients = 50M - 16.5M = 33.5M.<br>
                        <strong>Results:</strong> 16.5M with depression, 33.5M without.
                    </p>
                </div>
            </div>
        </section>

        <!-- Citations -->
        <section class="bg-white dark:bg-gray-800 rounded-2xl shadow-md p-6 fade-in">
            <h2 class="text-xl font-semibold mb-3">Sources & Citations</h2>
            <ul class="text-sm text-gray-600 dark:text-gray-300 space-y-1">
                <li><a href="https://www.flowneuroscience.com/" class="text-blue-500 hover:underline" target="_blank">Flow Neuroscience Official Website</a></li>
                <li><a href="https://www.credenceresearch.com/report/epilepsy-monitoring-devices-market" class="text-blue-500 hover:underline" target="_blank">Credence Research: Epilepsy Monitoring Devices Market</a></li>
                <li><a href="https://www.openpr.com/news/3635127/transcranial-direct-current-stimulation-market-to-reach-usd" class="text-blue-500 hover:underline" target="_blank">openPR: tDCS Market</a></li>
                <li><a href="https://www.siliconrepublic.com/start-ups/flow-neuroscience-series-a-funding" class="text-blue-500 hover:underline" target="_blank">Silicon Republic: Flow Neuroscience Series A</a></li>
                <li><a href="https://www.selectscience.net/article/medical-device-company-flow-neuroscience-raises-usd1-5m-to-transform-treatment-of-depression" class="text-blue-500 hover:underline" target="_blank">SelectScience: Flow Neuroscience Seed Funding</a></li>
                <li><a href="https://www.epilepsy.com/complications-risks/moods-behavior/depression" class="text-blue-500 hover:underline" target="_blank">Epilepsy Foundation: Depression and Epilepsy</a></li>
                <li><a href="https://www.theguardian.com/society/2025/jan/11/is-a-brain-stimulation-headset-the-answer-to-depression" class="text-blue-500 hover:underline" target="_blank">Guardian: Flow Neuroscience NHS Trials</a></li>
                <li><a href="https://www.medscape.com/viewarticle/diy-brain-stim-growing-popularity-safe-effective-2024a1000ij5" class="text-blue-500 hover:underline" target="_blank">Medscape: tDCS Safety and Efficacy</a></li>
                <li><a href="https://www.leicspart.nhs.uk/about/news/lpt-pilots-new-innovative-headsets-help-to-treat-patients-with-severe-depression/" class="text-blue-500 hover:underline" target="_blank">Leicestershire Partnership NHS Trust: Flow Pilot</a></li>
                <li><a href="https://www.fortunebusinessinsights.com/epilepsy-drugs-market-106908" class="text-blue-500 hover:underline" target="_blank">Fortune Business Insights: Epilepsy Treatment Market</a></li>
            </ul>
        </section>
    </div>

    <script>
        function toggleCollapsible(id) {
            const content = document.getElementById(id);
            content.classList.toggle('active');
        }

        function initializeFlowMedicalCharts() {
            const isDarkMode = document.documentElement.classList.contains('dark');
            const textColor = isDarkMode ? '#ffffff' : '#666666';
            const gridColor = isDarkMode ? '#374151' : '#e5e7eb';

            // Market Growth Chart
            new Chart(document.getElementById('flowmedical-market-growth').getContext('2d'), {
                type: 'line',
                data: {
                    labels: ['2023', '2024', '2025', '2026', '2027', '2028', '2029', '2030', '2031'],
                    datasets: [{
                        label: 'Epilepsy Monitoring Devices Market ($M)',
                        data: [520.0, 551.1, 582.5, 615.7, 650.8, 687.9, 727.1, 768.5, 812.3, 858.67],
                        borderColor: '#3B82F6',
                        backgroundColor: 'rgba(59, 130, 246, 0.2)',
                        fill: true,
                        tension: 0.4
                    }, {
                        label: 'tDCS Market ($B)',
                        data: [1.346, 1.471, 1.608, 1.757, 1.920, 2.099, 2.294, 2.507, 2.742],
                        borderColor: '#EC4899',
                        backgroundColor: 'rgba(236, 72, 153, 0.1)',
                        fill: true,
                        tension: 0.4,
                        yAxisID: 'y1'
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        legend: { labels: { color: textColor } },
                        tooltip: {
                            callbacks: {
                                label: function(context) {
                                    if (context.dataset.label.includes('tDCS')) {
                                        return `${context.dataset.label}: ${context.raw}B`;
                                    } else {
                                        return `${context.dataset.label}: ${context.raw}M`;
                                    }
                                }
                            }
                        }
                    },
                    scales: {
                        x: { ticks: { color: textColor }, grid: { color: gridColor } },
                        y: {
                            ticks: { color: textColor, callback: value => `${value}M` },
                            grid: { color: gridColor },
                            title: { display: true, text: 'Epilepsy Market ($M)', color: textColor }
                        },
                        y1: {
                            position: 'right',
                            ticks: { color: textColor, callback: value => `${value}B` },
                            grid: { drawOnChartArea: false, color: gridColor },
                            title: { display: true, text: 'tDCS Market ($B)', color: textColor }
                        }
                    }
                }
            });

            // Comorbidity Reach Chart
            new Chart(document.getElementById('flowmedical-comorbidity-reach').getContext('2d'), {
                type: 'doughnut',
                data: {
                    labels: ['Epilepsy w/ Depression (33%)', 'Other Epilepsy Patients'],
                    datasets: [{
                        data: [16.5, 33.5],
                        backgroundColor: ['#10B981', '#D1D5DB']
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        legend: { labels: { color: textColor } },
                        tooltip: {
                            callbacks: {
                                label: function(context) {
                                    return `${context.label}: ${context.raw} million patients`;
                                }
                            }
                        },
                        subtitle: {
                            display: true,
                            text: 'Source: Epilepsy Foundation, ~33% comorbidity',
                            padding: { top: 10, bottom: 0 },
                            font: { size: 12, style: 'italic' },
                            color: textColor
                        }
                    }
                }
            });

            // tDCS Technology Adoption Chart
            new Chart(document.getElementById('flowmedical-tech-adoption').getContext('2d'), {
                type: 'bar',
                data: {
                    labels: ['2021', '2022', '2023', '2024', '2025'],
                    datasets: [{
                        label: 'Flow tDCS Users (thousands)',
                        data: [5, 8, 11, 14, 18],
                        backgroundColor: 'rgba(236, 72, 153, 0.7)'
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        legend: { labels: { color: textColor } },
                        tooltip: {
                            callbacks: {
                                label: context => `Users: ${context.raw}k`
                            }
                        },
                        subtitle: {
                            display: true,
                            text: 'Source: Flow Neuroscience (2024, estimated)',
                            padding: { top: 10, bottom: 0 },
                            font: { size: 12, style: 'italic' },
                            color: textColor
                        }
                    },
                    scales: {
                        x: { ticks: { color: textColor }, grid: { color: gridColor } },
                        y: {
                            ticks: { color: textColor },
                            grid: { color: gridColor },
                            title: { display: true, text: 'Users (thousands)', color: textColor }
                        }
                    }
                }
            });

            // Funding Timeline Chart
            new Chart(document.getElementById('flowmedical-funding').getContext('2d'), {
                type: 'bar',
                data: {
                    labels: ['Seed Round (2018)', 'Series A (Aug 2021)'],
                    datasets: [{
                        label: 'Funding Amount (USD Million)',
                        data: [1.5, 9],
                        backgroundColor: ['rgba(59, 130, 246, 0.7)', 'rgba(16, 185, 129, 0.7)']
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        legend: { display: false },
                        tooltip: {
                            callbacks: {
                                label: context => `Funding: ${context.raw}M USD`
                            }
                        },
                        subtitle: {
                            display: true,
                            text: 'Sources: SelectScience (Seed), Silicon Republic (Series A)',
                            padding: { top: 10, bottom: 0 },
                            font: { size: 12, style: 'italic' },
                            color: textColor
                        }
                    },
                    scales: {
                        x: { ticks: { color: textColor }, grid: { color: gridColor } },
                        y: {
                            ticks: { color: textColor, callback: value => `${value}M` },
                            grid: { color: gridColor }
                        }
                    }
                }
            });
        }


        
        // Initialize charts on page load
        document.addEventListener('DOMContentLoaded', initializeFlowMedicalCharts);
        //  initializeFlowMedicalCharts()
    </script>
</body>
</html>